# Phase 1/2a Two-Arm Dose-Escalation Study of BAX69 in Subjects With Malignant Ascites of Ovarian Cancer

> **NCT02540356** · PHASE1,PHASE2 · TERMINATED · sponsor: **Baxalta now part of Shire** · enrollment: 2 (actual)

## Conditions studied

- Refractory Ovarian Cancer With Recurrent Symptomatic Malignant Ascites

## Interventions

- **BIOLOGICAL:** BAX69 Single-Route Arm
- **BIOLOGICAL:** BAX69 Double-Route Arm

## Key facts

- **NCT ID:** NCT02540356
- **Lead sponsor:** Baxalta now part of Shire
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-11-02
- **Primary completion:** 2016-05-26
- **Final completion:** 2016-05-26
- **Target enrollment:** 2 (ACTUAL)
- **Last updated:** 2021-01-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02540356

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02540356, "Phase 1/2a Two-Arm Dose-Escalation Study of BAX69 in Subjects With Malignant Ascites of Ovarian Cancer". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02540356. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*